Response of Bowen Disease to ALA-PDT Using a Single and a 2-Fold Illumination Scheme

Haas, E; Sterenborg, Henricus J. C. M.; Neumann, H. A. Martino; Robinson, Dominic J.

doi:10.1001/archderm.143.2.264

Cited by 44 publications

(58 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…69 A number of studies have highlighted the effectiveness of 1 to 2 ALA-PDT treatment sessions in treating SCC in situ, with complete response at 12 months ranging from 80% to 100%. [70][71][72] ALA-PDT has shown particular efficacy in treating SCC in situ located on the lower leg, 71 a region of poor healing with other therapies. In a large randomized controlled trial that included 225 SCC in situ patients, MAL-PDT produced an 80% complete response rate by 12 months of follow-up, along with a good or excellent cosmetic outcome in 97% of cases.…”

Section: Photodynamic Therapymentioning

confidence: 99%

Non-melanoma Skin Cancer in Canada Chapter 5: Management of Squamous Cell Carcinoma

et al. 2015

View full text Add to dashboard Cite

Background Squamous cell carcinoma (SCC) is the second-most common form of non-melanoma skin cancer (NMSC). Objective To provide guidance to Canadian health care practitioners regarding management of SCCs. Methods Literature searches and development of graded recommendations were carried out as discussed in the accompanying introduction (chapter 1 of the NMSC guidelines). Results SCCs are sometimes confined to the epidermis, but they can also invade nearby tissues and, in some cases, metastasize to neighbouring lymph nodes or other organs. This chapter discusses the natural history, staging, prognosis, and management of SCC—a tumour type that is less common but typically more aggressive than BCC. For this reason, margin control is strongly preferred in treating SCCs. Conclusions Although approaches such as cryosurgery and radiation therapy may be considered for some patients, surgical excision—sometimes coupled with radiation—remains the cornerstone of SCC management. Patients with high-risk SCC may also be considered for referral to an appropriate multidisciplinary clinic.

show abstract

Section: Photodynamic Therapymentioning

confidence: 99%

Non-melanoma Skin Cancer in Canada Chapter 5: Management of Squamous Cell Carcinoma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…[69][70][71][72][73] Results for ALA, [69][70][71][72] and MAL 73 are presented separately; AEs were not reported for the only trial using verteporfin.…”

Section: Results Of Safetymentioning

confidence: 99%

“…However, comparison of total pain over time resulted in no statistically significant difference in the median pain scores between the two treatment groups. In the trial by de Haas et al, 69 pain during treatment was experienced by five patients in the twofold-illumination group and by none of the patients in the single-illumination group. In the trial by Morton et al 70 comparing red and green light, no significant difference in pain was observed between the treatment groups.…”

Section: Ala-pdtmentioning

confidence: 92%

“…69 In the trial by Morton et al 71 comparing PDT with cryotherapy, PDT resulted in statistically significantly less pain during treatment (p = 0.01). Six patients in this trial who received both treatments reported PDT as less painful.…”

Section: Ala-pdtmentioning

confidence: 99%

“…Five out of seven trials were published within the last 6 years, 57,68,69,72,73 with two being considerably older. 70,71 All except one trial had fewer than 50 patients.…”

Section: Study Qualitymentioning

confidence: 99%

See 2 more Smart Citations

A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett’s oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin

Fayter

Corbett²,

Heirs³

et al. 2010

Health Technol Assess

128

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address. Paying by credit cardYou can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeT he Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of project...

show abstract

Interventions for cutaneous Bowen's disease

Bath‐Hextall

Matin

Wilkinson

et al. 2013

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Overall, there has been very little good-quality research on treatments for Bowen's disease. There is limited evidence from single studies to suggest MAL-PDT is an effective treatment. Although cosmetic outcomes appear favourable with PDT, five-year follow-up data are needed. Significantly more lesions cleared with MAL-PDT compared to cryotherapy. No significant difference in clearance was seen when MAL-PDT was compared with 5-FU, but one study found a significant difference in clearance in favour of ALA-PDT when compared to 5-FU. There was no significant difference in clearance when cryotherapy was compared to 5-FU.The lack of quality data for surgery and topical cream therapies has limited the scope of this review to one largely about PDT studies. The age group, number, and size of lesions and site(s) affected may all influence therapeutic choice; however, there was not enough evidence available to provide guidance on this. More studies are required in the immunosuppressed populations as different therapeutic options may be preferable. Specific recommendations cannot be made from the data in this review, so we cannot give firm conclusions about the comparative effectiveness of treatments.

show abstract

Response of Bowen Disease to ALA-PDT Using a Single and a 2-Fold Illumination Scheme

Cited by 44 publications

References 12 publications

Non-melanoma Skin Cancer in Canada Chapter 5: Management of Squamous Cell Carcinoma

Non-melanoma Skin Cancer in Canada Chapter 5: Management of Squamous Cell Carcinoma

A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett’s oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin

Interventions for cutaneous Bowen's disease

Contact Info

Product

Resources

About